These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19353224)

  • 21. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis.
    Hsu PJ; Chen CH; Yeh SJ; Tsai LK; Tang SC; Jeng JS
    Cerebrovasc Dis; 2016; 42(1-2):117-21. PubMed ID: 27088493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
    Fan Y; Liao X; Pan Y; Dong K; Wang Y; Wang Y;
    J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):220-226. PubMed ID: 30366863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
    Matsuo R; Kamouchi M; Ago T; Hata J; Shono Y; Kuroda J; Wakisaka Y; Sugimori H; Kitazono T;
    Geriatr Gerontol Int; 2014 Oct; 14(4):954-9. PubMed ID: 24320947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
    Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does symptom onset to primary stroke center time goals affect stroke outcome?
    Chee B; Raman R; Ernstrom K; Guzik AK; Hemmen TM; Rapp KS; Meyer BC; Meyer DM
    J Stroke Cerebrovasc Dis; 2014; 23(5):993-1000. PubMed ID: 24103670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to guidelines by emergency medical services during transport of stroke patients receiving intravenous thrombolytic infusion.
    Asaithambi G; Chaudhry SA; Hassan AE; Rodriguez GJ; Suri MF; Qureshi AI
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e42-5. PubMed ID: 22572162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics and Outcomes of Patients who Refuse Intravenous Thrombolysis for Acute Ischemic Stroke - The San Diego Experience.
    von Kleist T; Meyer D; Rapp K; Meyer BC; Modir R
    J Stroke Cerebrovasc Dis; 2020 Nov; 29(11):105137. PubMed ID: 33066942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin.
    Mazya MV; Lees KR; Markus R; Roine RO; Seet RC; Wahlgren N; Ahmed N;
    Ann Neurol; 2013 Aug; 74(2):266-74. PubMed ID: 23744571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke.
    Uyttenboogaart M; Vroomen PC; Stewart RE; De Keyser J; Luijckx GJ
    J Neurol Sci; 2007 Mar; 254(1-2):28-32. PubMed ID: 17257623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eligibility determination for intravenous thrombolysis based on radiology interpretation report of the head CT scan in patients with acute ischemic stroke.
    Hassan AE; Majidi S; Janjua NA; Chaudhry SA; Tekle WG; Grigoryan M; Qureshi AI
    J Neuroimaging; 2014; 24(4):349-53. PubMed ID: 24015702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital].
    Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S
    No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
    Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.
    Audebert HJ; Kukla C; Vatankhah B; Gotzler B; Schenkel J; Hofer S; Fürst A; Haberl RL
    Stroke; 2006 Jul; 37(7):1822-7. PubMed ID: 16763192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?
    Pretnar Oblak J; Sabovic M; Frol S
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):768-773. PubMed ID: 30527792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.